MBP and COVID-19: Neurological manifestations in COVID-19 patients have been associated with the presence of autoantibodies against contactin-associated protein 2 (anti-Caspr2), GD1b ganglioside (anti-GD1b), myelin oligodendrocyte glycoprotein (anti-MOG), and myelin basic protein (anti-ObM) [85,86,87].